Osteoporosis and Activation Study of the Immune System in HIV - OASIS-HIV

niversitair Medisch Centrum Utrecht0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•-Successful participation in the *A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects* study (UMCU METC number 13-429):
•- HIV-1 infected subjects regardless of race or ethnicity.
•- Use of one of the following taken as a stable, continuous, NRTI-containing ARV regimen for >= 3 years are allowed (within-class change of agents other than TDF within 3 years of study entry are permitted as specified):
•- a TDF plus PI/r-containing regimen including subjects who switched from one TDF
•plus PI/r regimen to another TDF plus PI/r regimen.
•- a TDF plus non-PI/r-containing regimen including subjects who switched from one
•TDF plus non-PI/r regimen to another TDF plus non-PI/r regimen.
•- a Non-TDF NRTI plus a PI/r-containing regimen including subjects who switched
•from one non-TDF NRTI plus PI/r regimen to another non-TDF NRTI regimen plus
•PI/r regimen.
•- a Non-TDF NRTI plus a non-PI/r-containing regimen including subjects who
•switched from one non-TDF NRTI plus non-PI/r regimen to another non-TDF NRTI
•regimen plus non-PI/r regimen.
•- Male subjects must be >= 50 years of age.
•- Female subjects must be postmenopausal.
•- Adequate records available to evaluate medical history prior to study entry, including:
•- prior ARVs and other medications
•- risk factors for osteoporosis and osteopenia
•- Able to give informed consent, which must be obtained prior to initiation of any study procedures.

发起方

niversitair Medisch Centrum Utrecht